Zack Armen, Vice President, Head of Corporate Development and Investor Relations at Agenus, shared a post on LinkedIn:
“Excited to announce this important tranasction that provides us with the capital needed to bring BOT+BAL to patients in need in MSS colon cancer, one of the most prevalent and growing cancers where other immunotherapies have not been effective nor approved.
We thank our team and our new and existing investors for their support and look forward to the mission ahead to deliver on the promise of BOT+BAL.”
For a deeper look at Agenus’ latest announcement and the ROBBIN trial strategy, read the full OncoDaily coverage here: Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer
